secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001193125-25-001809
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA adds liver injury warning to PYRUKYND label for PK deficiency
-----------------------------------------------------------------

- FDA approved update to PYRUKYND USPI: liver injury observed in patients with another condition at higher doses.
- New Warnings: obtain liver tests before initiation, monthly for first 6 months, interrupt if ALT >5x ULN.
- All patients with liver injury discontinued PYRUKYND and improved upon discontinuation.
- Adverse Reactions section updated to reflect hepatocellular injury in another condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312525001809/0001193125-25-001809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312525001809/d911895d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-001809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer